Genmab A/s is altering its pipeline, announcing that the company has agreed to acquire three pre-clinical stage targeted antibodies from iDD Biotech and the company’s decision to drop the option to co-develop HuMax-TAC-ADC with ADC Therapeutics Sarl. Genmab said that it has entered into an agreement to purchase antibodies and …